Baxter Biotech Technology SARL
Records under this name other than patents Baxter Biotech Technology SARL holds now: patents now held by others, patents whose terms have ended, and its applications, pending or abandoned.
Back to Baxter Biotech Technology SARL
| Patent | Title | Status | Expires | Confidence |
|---|---|---|---|---|
| US 6,136,565 | Methods of reducing the levels of protoporphyrin IX in recombinant hemoglobin preparations Term ended Term ended Oct 18, 2019 · From the USPTO record | Term ended | Term ended Oct 18, 2019 | From the USPTO record |
| US 6,171,826 | Methods of controlling beta dimer formation in hemoglobin Term ended Term ended May 14, 2019 · From the USPTO record | Term ended | Term ended May 14, 2019 | From the USPTO record |
| US 6,242,417 | Stabilized compositions containing hemoglobin Term ended Term ended Jun 5, 2018 · From the USPTO record | Term ended | Term ended Jun 5, 2018 | From the USPTO record |
| US 6,160,098 | Method for control of functionality during cross-linking of hemoglobins Term ended Term ended May 29, 2018 · From the USPTO record | Term ended | Term ended May 29, 2018 | From the USPTO record |
| US 6,114,505 | Hemoglobin mutants that reduce heme loss Formerly held Term ended Term ended Apr 22, 2018 · From the USPTO record | Term ended | Term ended Apr 22, 2018 | From the USPTO record |
| US 6,022,849 | Mutant recombinant hemoglobins containing heme pocket mutations Term ended Term ended Feb 8, 2017 · From the USPTO record | Term ended | Term ended Feb 8, 2017 | From the USPTO record |
| US 6,828,125 | DNA encoding fused di-alpha globins and use thereof Lapsed on the fee record Ended Dec 7, 2016 · From the USPTO record | Lapsed on the fee record | Ended Dec 7, 2016 | From the USPTO record |
| US 6,670,323 | Reduced side-effect hemoglobin compositions Formerly held Lapsed on the fee record Ended Dec 30, 2015 · From the USPTO record | Lapsed on the fee record | Ended Dec 30, 2015 | From the USPTO record |
| US 6,455,676 | Hemoglobin mutants with increased soluble expression and/or reduced nitric oxide scavenging Lapsed on the fee record Ended Sep 24, 2014 · From the USPTO record | Lapsed on the fee record | Ended Sep 24, 2014 | From the USPTO record |
| US 7,049,406 | Hemoglobin mutants with increased soluble expression and/or reduced nitric oxide scavenging Lapsed on the fee record Ended May 23, 2014 · From the USPTO record | Lapsed on the fee record | Ended May 23, 2014 | From the USPTO record |